Table 1—

Clinical characteristics of the 15 patients with MODY3 participating in the study

PatientSexAge (years)FPG (mmol/l)*A1C (%)BMI (kg/m2)Fat mass (%)Systolic BP (mmHg)*Diastolic BP (mmHg)*Antihyperglycemic medication
1F23.94.3/4.0/4.35.425.03413081None
2F44.97.0/8.4/7.46.622.43210970None
3F30.810.8/−8.6/11.38.122.63011082Meal-time regular insulin
4M34.27.0/6.2/6.86.421.91711577Acarbose 25 mg twice a day
5M42.512.2/11.3/13.58.724.32111886Glimepiride 2 mg once daily
6F50.611.3/10.3/−8.89.123.43110471Glibenclamide 4 35 mg/day
7F41.15.3/6.4/6.16.728.23612181None
8F62.65.2/4.4/4.86.524.73414483Glimepiride 1 mg once daily
9M32.97.5/7.3/8.57.822.31513678None
10M46.57.9/7.8/8.1723.922166106None
11M66.116.2/15.5/14.29.923.42316588Glibenclamide 35 mg/day
12F40.28.3/8.4/7.85.916.71611369Acarbose 50 mg × 3
13F47.39.4/8.0/7.36.119.81812370Acarbose 50 mg × 3
14F20.05.4/7.3/5.8923.12811267Glimepiride 1 mg once daily
15F28.05.0/6.5/7.66.721.22512570None
Median (interquartile range)41.0 (16.5)7.9 (3.9)6.7 (2.3)23.1 (2.4)25 (14)121 (24)78 (13)
  • *

    * FPG is shown for each visit (ordered: nateglinide/glibenclamide/placebo, although the patients received the three drugs in random order).

  • Medication for coronary heart disease including β-blockers.

  • Antihypertensive medication. BP, blood pressure.